Aligos Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aligos Therapeutics's estimated annual revenue is currently $4M per year.
- Aligos Therapeutics's estimated revenue per employee is $40,303
- Aligos Therapeutics's total funding is $308.6M.
- Aligos Therapeutics's current valuation is $139.8M. (January 2022)
Employee Data
- Aligos Therapeutics has 99 Employees.
- Aligos Therapeutics grew their employee count by -7% last year.
Aligos Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Oncology | Reveal Email/Phone |
2 | EVP, Translational Safety Sciences | Reveal Email/Phone |
3 | EVP, Head Chemical Operations | Reveal Email/Phone |
4 | Head Bioanalytical Sciences and Outsourcing | Reveal Email/Phone |
5 | VP, Early Compound Development, Belgian Site Head | Reveal Email/Phone |
6 | VP Finance | Reveal Email/Phone |
7 | VP, Head People & Culture | Reveal Email/Phone |
8 | VP, Finance | Reveal Email/Phone |
9 | VP, Investor Relations and Corporate Communications | Reveal Email/Phone |
10 | Director - Process Chemistry | Reveal Email/Phone |
Aligos Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Aligos Therapeutics?
Company Mission: To become a world leader in the development of targeted, curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Scientific Overview: Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.
keywords:N/A
$308.6M
Total Funding
99
Number of Employees
$4M
Revenue (est)
-7%
Employee Growth %
$139.8M
Valuation
N/A
Accelerator
Aligos Therapeutics News
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in...
By Chris Wack. Aligos Therapeutics Inc. said it has discontinued development of its ALG-020572 drug candidate, which was being studied in...
Aligos Therapeutics has stopped dosing of subjects in the first chronic hepatitis B (CHB) group of the Phase I ALG-020572-401 clinical trial...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21M | 100 | 4% | N/A |
#2 | $27.5M | 102 | 1% | N/A |
#3 | $75M | 104 | 7% | N/A |
#4 | $14.9M | 113 | 16% | $173M |
#5 | $37.1M | 113 | 82% | N/A |